Comparison of the Effects of SK&F 93479 and Phenobarbitone Treatment on Thyroid Toxicity and Hepatic Thyroid Hormone Metabolising Enzymes in the Rat

  • C. G. Brown
  • D. M. Lee
  • C. A. Jones
  • C. K. Atterwill
Part of the Archives of Toxicology book series (TOXICOLOGY, volume 12)

Abstract

Deiodination and glucuronidation are major routes of T3 and T4 metabolism in rodents and both the deiodinases and uridine diphosphate glucuronyl transferase (UDP-GT) are affected by drug treatment (see review by Cavalieri and Pitt Rivers 1981). The phenobarbitone (PB)-induced thyroid stimulation and thyroid tumour-promoting potential in rats (Hiasa et al. 1982) follows from enhanced hepatic thyroxine elimination (Oppenheimer et al. 1968) which may result in part from stimulation of UDP-GT activity, since hepatic T4 conjugation is rate limiting for biliary T4 clearance. PB is also known to enhance the UDP-GT isoenzyme activity preferentially conjugating T4 and para-nitrophenol (PNP) in rats (Watkins et al. 1982). The histamine H2-antagonist SK&F 93479 (2-(2-(5-(dimethylaminome-thyl)furan-2-ylmethylthio)-ethylamino)-5-(6-methylpyrid-3-ylmethyl)-pyrimidin-4-one trihydrochloride) has been previously shown to produce similar thyroid lesions to PB at toxicological doses (see Brown et al. 1987), resulting from rapid increases in T4 clearance (approx. 6 h following treatment) and subsequent increases in TSH drive (approx. 24 h following treatment). It was further demonstrated that the increased T4 clearance did not correlate with changes in hepatic or renal 5′-deiodinase activity (Jones et al. 1987). Therefore, the onset of increases in T4 clearance produced by the two drugs in rats has been compared with changes in both hepatic UDP-GT and β-glucuronidase activities in an attempt to define the exact hepatocellular mechanism associated with the endocrinological changes.

Keywords

Histamine Phen Furan Phenobarbital Thyroxine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Brown CG, Harland RF, Major IR, Atterwill CK (1987) Effects of toxic doses of a novel histamine (H2) antagonist on the rat thyroid gland. Fd Chem Toxic 25:787–794CrossRefGoogle Scholar
  2. Cavalieri RR, Pit-Rivers R (1981) The effects of drugs on the distribution and metabolism of thyroid hormones. Pharmacol Rev 33:55–79PubMedGoogle Scholar
  3. Hiasa Y, Kitahori Y, Oshima M et al. (1982) Promoting effects of Phénobarbital and barbital on development of thyroid tumours in rats treated with N-bis (2-hydroxypropyl) nitrosoam-ine. Carcionogenesis 3:1187–1190CrossRefGoogle Scholar
  4. Jones CA, Brown CG, Atterwill CK (1987) Thyroid toxicity and iodothyronine deiodination. Arch Toxicol [Suppl] 11:250–252Google Scholar
  5. Oppenheimer JH, Bernstein G, Surks MI (1968) Increased thyroxine turnover and thyroidal function after stimulation of hepatocellular binding of thyroxine by phenobarbital. Clin Invest Med 47:1399–1406CrossRefGoogle Scholar
  6. Topliss DJ, Kolliniatis E, Stockigt JR (1987) Drug inhibition of rapid T3 uptake by cultured rat hepatocytes. Ann Endocrinol (Paris) 48(2): 114Google Scholar
  7. Watkins JB, Gregus Z, Thompson TN, Klaassen CD (1982) Introduction of studies on the functional heterogeneity of rat liver UDP-glucuronosyl transferases. Toxicol Appl Pharmacol 64:439–446PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 1988

Authors and Affiliations

  • C. G. Brown
    • 1
  • D. M. Lee
    • 1
  • C. A. Jones
    • 1
  • C. K. Atterwill
    • 1
  1. 1.Smith Kline & French Research LtdThe Frythe, Welwyn, HertsUK

Personalised recommendations